1,2,3-triazole compound and antiviral agent
1,2,3-triazole compounds effectively inhibit viral replication by mimicking nucleoside triphosphates, addressing the challenge of selective toxicity and drug resistance in existing antiviral drugs, with applications in treating and preventing viral infections.
Patent Information
- Application Number
- JP2023078168
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing antiviral drugs face challenges in selectively targeting viruses within host cells due to their reliance on host metabolic systems, and there is a need for new drugs to combat drug-resistant viruses and emerging viral strains.
Development of 1,2,3-triazole compounds and their salts, which exhibit antiviral activity by inhibiting viral replication through triphosphorylation by thymidine kinase, mimicking nucleoside triphosphates and interfering with viral DNA or RNA polymerase functions.
The 1,2,3-triazole compounds demonstrate potent antiviral activity against various viruses, including herpesviruses, while maintaining low cytotoxicity to host cells, offering a potential therapeutic and prophylactic solution for viral infections.
Smart Images

Figure 2024162557000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to 1,2,3-triazole compounds. [Background technology]
[0002] Compounds in which the structure of nucleosides, which are components of nucleic acids, is partially chemically modified are sometimes used as antiviral drugs. For example, Patent Document 1 discloses acyclovir formulated as an eye ointment. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] Special Publication No. 2004-503485 Summary of the Invention [Problem to be solved by the invention]
[0004] Unlike bacteria, which grow outside of host cells, viruses depend on host cells for much of their metabolic system for growth, making it difficult to create drugs that show excellent selective toxicity. In addition, the development of new drugs is desired to combat viruses that have acquired resistance through mutation and new types of viruses. For this reason, new technologies with antiviral activity are needed. [Means for solving the problem]
[0005] The present disclosure can be realized in the following forms.
[0006] (1) According to one aspect of the present disclosure, there is provided a 1,2,3-triazole compound or a salt thereof. The 1,2,3-triazole compound is represented by general formula (1). [ka] (In the formula, X represents one member selected from the group consisting of adenine, thymine, uracil, cytosine, and guanine; R represents an alkyl group having from 1 to 4 carbon atoms and substituted with a substituent, or an aryl group substituted with the aforementioned substituent, and the aforementioned substituent is a hydroxyl group, or an alkyl group having from 1 to 4 carbon atoms and substituted with a hydroxyl group.) The 1,2,3-triazole compound or a salt thereof in this form has antiviral activity.
[0007] (2) In the 1,2,3-triazole compound or salt thereof described in (1) above, X may be adenine. The 1,2,3-triazole compound or salt thereof in this form has excellent antiviral activity.
[0008] (3) In the 1,2,3-triazole compound or salt thereof described in (1) above, X may be one selected from the group consisting of thymine, uracil, and cytosine. The 1,2,3-triazole compound or salt thereof in this form has excellent antiviral activity.
[0009] (4) In the 1,2,3-triazole compound or salt thereof described in (2) above, R may be an aryl group substituted with the aforementioned substituent. The 1,2,3-triazole compound or salt thereof in this form has excellent antiviral activity.
[0010] (5) In the 1,2,3-triazole compound or salt thereof described in (2) or (4), R may be a phenyl group substituted with the substituent. The 1,2,3-triazole compound or salt thereof in this form has a more excellent antiviral activity.
[0011] (6) In the 1,2,3-triazole compound or salt thereof according to (2), (4) or (5), the substituent may be an alkyl group having 2 to 3 carbon atoms and substituted with two or more hydroxyl groups. The 1,2,3-triazole compound or salt thereof in this form has even more excellent antiviral activity.
[0012] (7) In the 1,2,3-triazole compound or salt thereof described in (2) above, R may be an alkyl group having 1 to 2 carbon atoms and substituted with the substituent. The 1,2,3-triazole compound or salt thereof in this form has excellent antiviral activity.
[0013] (8) In the 1,2,3-triazole compound or salt thereof according to (7) above, the substituent may be a hydroxyl group. The 1,2,3-triazole compound or salt thereof in this form has a more excellent antiviral activity.
[0014] According to another aspect of the present disclosure, there is provided an antiviral agent comprising the 1,2,3-triazole compound or a salt thereof according to any one of (1) to (8) above.
[0015] The present disclosure can be realized in various forms, for example, a method for producing a 1,2,3-triazole compound, a method for producing an antiviral agent, a pharmaceutical composition containing a 1,2,3-triazole compound or a salt thereof, a preventive agent for viral infections containing a 1,2,3-triazole compound or a salt thereof, a therapeutic agent for viral infections containing a 1,2,3-triazole compound or a salt thereof, use of a 1,2,3-triazole compound or a salt thereof for producing an antiviral agent, use of a 1,2,3-triazole compound or a salt thereof for producing a pharmaceutical composition, a method for preventing a viral infection, a method for treating a viral infection, etc. [Brief description of the drawings]
[0016] [Figure 1] FIG. 1 is an explanatory diagram showing the results of antiviral activity evaluation. [Diagram 2] FIG. 1 is an explanatory diagram showing the results of cytotoxicity evaluation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] According to one embodiment of the present disclosure, there is provided a 1,2,3-triazole compound or a salt thereof. The 1,2,3-triazole compound is represented by general formula (1). In the formula, X represents one selected from the group consisting of adenine, thymine, uracil, cytosine, and guanine, R represents an alkyl group having 1 to 4 carbon atoms and substituted with a substituent, or an aryl group substituted with a substituent, and the substituent is a hydroxyl group or an alkyl group having 1 to 4 carbon atoms and substituted with a hydroxyl group.
[0018] [ka]
[0019] In the present disclosure, the "alkyl group having 1 to 4 carbon atoms" may be linear or branched. The alkyl group having 1 to 4 carbon atoms is not particularly limited, but examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group.
[0020] In the present disclosure, the term "aryl group" refers to a monovalent aromatic hydrocarbon group. The aryl group is not particularly limited, but examples thereof include a phenyl group, a naphthyl group, and an anthryl group. The naphthyl group includes, for example, a 1-naphthyl group and a 2-naphthyl group. The anthryl group includes, for example, a 1-anthryl group, a 2-anthryl group, and a 9-anthryl group.
[0021] From the viewpoint of synthesis of the 1,2,3-triazole compound, X is preferably adenine or a pyrimidine base (thymine, uracil, cytosine). In the form in which X is adenine or guanine, it is preferable that the compound has a structure shown in the following general formula (2) or (3), respectively. In other words, the 1,2,3-triazole compound containing a purine base preferably has a structure in which a 1,2,3-triazole ring is bonded to the carbon at the 9th position of the purine base via a methyl group. In addition, in the general formulas (2) and (3), R represents an alkyl group having 1 to 4 carbon atoms substituted with a substituent, or an aryl group substituted with a substituent, and the substituent is a hydroxyl group, or an alkyl group having 1 to 4 carbon atoms substituted with a hydroxyl group.
[0022] [ka]
[0023] [ka]
[0024] In the form in which X is thymine, uracil or cytosine, it is preferable that the compound has a structure shown in the following general formulas (4) to (6), respectively. In other words, the 1,2,3-triazole compound containing a pyrimidine base preferably has a structure in which a 1,2,3-triazole ring is bonded to the carbon at position 1 of the pyrimidine base via a methyl group. In addition, in the general formulas (4) to (6), R represents an alkyl group having 1 to 4 carbon atoms substituted with a substituent, or an aryl group substituted with a substituent, and the substituent is a hydroxyl group or an alkyl group having 1 to 4 carbon atoms substituted with a hydroxyl group.
[0025] [ka]
[0026] [ka]
[0027] [ka]
[0028] In the form where X is adenine, that is, in the 1,2,3-triazole compound containing adenine, R is preferably an alkyl group having 1 to 2 carbon atoms substituted with one or more substituents, or an aryl group substituted with one or more substituents, from the viewpoint of interaction with the target enzyme and synthesis of the 1,2,3-triazole compound. In this form, the aryl group is preferably an aryl group having 6 to 14 carbon atoms, more preferably an aryl group having 6 to 10 carbon atoms, and even more preferably a phenyl group, from the viewpoint of interaction with the target enzyme. Therefore, in the form where X is adenine, R is particularly preferably a phenyl group substituted with one or more substituents.
[0029] In the 1,2,3-triazole compound containing adenine, the substituent in the "alkyl group having 1 to 4 carbon atoms substituted with a substituent" is preferably a hydroxyl group or an alkyl group having 1 to 2 carbon atoms substituted with a hydroxyl group, more preferably a hydroxyl group, from the viewpoint of interaction with the target enzyme. In the 1,2,3-triazole compound containing adenine, the substituent in the "aryl group substituted with a substituent" is preferably an alkyl group having 1 to 3 carbon atoms substituted with a hydroxyl group, more preferably an alkyl group having 2 to 3 carbon atoms substituted with two or more hydroxyl groups, from the viewpoint of interaction with the target enzyme.
[0030] In the 1,2,3-triazole compound containing adenine, the number of the above-mentioned substituents in the "alkyl group having 1 to 4 carbon atoms substituted with a substituent" and the "aryl group substituted with a substituent" is, from the viewpoint of interaction with the target enzyme, preferably from 1 to 4, more preferably from 1 to 3, and even more preferably from 1 to 2. When the number of the substituents is 2 or more, the respective substituents may be the same or different from each other.
[0031] In a 1,2,3-triazole compound containing adenine, the total number of carbon atoms in the "alkyl group having 1 to 4 carbon atoms substituted with a substituent", in other words, the total number of carbon atoms in the alkyl group including the substituent, is preferably 1 to 6, more preferably 1 to 4, and even more preferably 1 to 2, from the viewpoint of interaction with a target enzyme.
[0032] In the 1,2,3-triazole compound containing adenine, the total number of carbon atoms in the "aryl group substituted with a substituent", in other words, the total number of carbon atoms in the aryl group including the substituent, is preferably 6 or more and 14 or less, more preferably 6 or more and 12 or less, even more preferably 7 or more and 10 or less, and particularly preferably 8 or more and 9 or less, from the viewpoint of the interaction with the target enzyme.
[0033] In the form in which X is a pyrimidine base, i.e., in the 1,2,3-triazole compound containing thymine, uracil or cytosine, R is preferably an alkyl group having 1 to 4 carbon atoms and substituted with one or more substituents, more preferably an alkyl group having 1 to 2 carbon atoms and substituted with one or more substituents, from the viewpoint of interaction with the target enzyme and synthesis of the 1,2,3-triazole compound. In the 1,2,3-triazole compound containing thymine, uracil or cytosine, the substituent in the "alkyl group having 1 to 4 carbon atoms and substituted with a substituent" is preferably a hydroxyl group or an alkyl group having 1 to 2 carbon atoms and substituted with a hydroxyl group, more preferably a hydroxyl group, from the viewpoint of interaction with the target enzyme.
[0034] In a 1,2,3-triazole compound containing thymine, uracil or cytosine, the number of the above-mentioned substituents in the "alkyl group having 1 to 4 carbon atoms substituted with a substituent" is preferably 1 to 4, more preferably 1 to 3, and even more preferably 1 to 2, from the viewpoint of interaction with a target enzyme. When the number of the substituents is 2 or more, each substituent may be the same or different from each other. In a 1,2,3-triazole compound containing thymine, uracil or cytosine, the total number of carbon atoms in the "alkyl group having 1 to 4 carbon atoms substituted with a substituent", in other words, the total number of carbon atoms of the alkyl group including the substituent, is preferably 1 to 6, more preferably 1 to 4, and even more preferably 1 to 2, from the viewpoint of interaction with a target enzyme.
[0035] The 1,2,3-triazole compound of the present disclosure may be in the form of a salt. The salt is not particularly limited, but may be, for example, a salt of a basic group such as an amino group, or an acidic group such as a hydroxyl group or a carboxyl group, and is preferably a pharmacologically acceptable salt.
[0036] The salt of the basic group is not particularly limited, but examples thereof include salts with inorganic acids and salts with organic acids. The inorganic acid is not particularly limited, but examples thereof include hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, etc. The organic acid is not particularly limited, but examples thereof include organic carboxylic acids such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, tartaric acid, aspartic acid, trichloroacetic acid, and trifluoroacetic acid; and sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid, and naphthalenesulfonic acid.
[0037] Salts of acidic groups are not particularly limited, and examples thereof include salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; and salts with nitrogen-containing organic bases such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, 4-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-ephenamine, and N,N'-dibenzylethylenediamine.
[0038] The 1,2,3-triazole compounds of the present disclosure include isomers such as optical isomers, geometric isomers, and tautomers. The 1,2,3-triazole compounds of the present disclosure also include hydrates, solvates, and their crystalline polymorphs. The 1,2,3-triazole compounds of the present disclosure also include pharmacologically acceptable prodrugs of the compounds represented by the above general formula (1). In the present disclosure, a pharmacologically acceptable prodrug means a compound having a group that can be converted to an amino group, a hydroxyl group, or the like by solvolysis or under physiological conditions. Examples of groups that form prodrugs include those described in Prog. Med., 5, 2157-2161 (1985) and "Drug Development" (Hirokawa Shoten, 1990) Vol. 7, Molecular Design 163-198.
[0039] A method for producing the compound represented by the above general formula (1) is described below. The compound represented by the above general formula (1) can be synthesized, for example, by the reaction steps shown below. More specifically, the compound represented by the above general formula (2) can be synthesized by first preparing an adenine derivative in which an azidomethyl group is introduced at the 9-position of adenine as shown below, and then using this adenine derivative. In this specification, "room temperature" usually means about 10°C to about 35°C.
[0040] [ka]
[0041] (Synthesis of Compound No. 1) Adenine is suspended in distilled water, sodium hydroxide and an aqueous formaldehyde solution are added, and the mixture is stirred at room temperature. The precipitated solid is washed with water and collected by suction filtration to obtain Compound No. 1.
[0042] (Synthesis of Compound No. 2) Compound No. 1 is suspended in N,N-dimethylformamide, thionyl chloride is added, and the mixture is stirred at room temperature. Excess thionyl chloride is decomposed by adding water under ice cooling, and the solvent is distilled off under reduced pressure. The precipitated solid is collected by suction filtration to obtain compound No. 2.
[0043] (Synthesis of Compound No. 3) Compound No. 2 is suspended in DMSO, sodium azide is added, and the mixture is stirred at about 80°C. The mixture is diluted with ethyl acetate and extracted with saturated saline. The mixture is dried over anhydrous sodium sulfate, and the solvent is removed under reduced pressure. Compound No. 3 (adenine derivative) can be obtained by filtering the precipitated solid with suction.
[0044] The compound represented by the above general formula (4) can be synthesized by first preparing a thymine derivative in which an azidomethyl group has been introduced at the 1-position of thymine as shown below, and then using this thymine derivative.
[0045] [ka]
[0046] (Synthesis of Compound No. 4) Thymine is suspended in pyridine and acetonitrile, and benzoyl chloride is added dropwise under ice cooling, followed by stirring at room temperature. Methanol is added and stirred, and the solvent is removed under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound number 4.
[0047] (Synthesis of Compound No. 5) Compound No. 4 is suspended in an aqueous formaldehyde solution and heated to reflux. After cooling to room temperature, the solution is refrigerated. The precipitated solid is washed with an aqueous formaldehyde solution and collected by suction filtration to obtain compound No. 5.
[0048] (Synthesis of Compound No. 6) Compound No. 5 is dissolved in N,N-dimethylformamide, thionyl chloride is added dropwise under ice cooling, and the mixture is stirred at room temperature. Water is added under ice cooling, and the mixture is neutralized with a saturated aqueous solution of sodium bicarbonate. The mixture is diluted with chloroform, and then extracted with a saturated aqueous solution of sodium bicarbonate. The mixture is washed with saturated saline, and the solvent is distilled off under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound No. 6.
[0049] (Synthesis of Compound No. 7) Compound No. 6 is dissolved in acetone, sodium azide is added, and the mixture is stirred at room temperature. Insoluble matter is removed by suction filtration, and the filtrate is concentrated under reduced pressure. The residue is diluted with ethyl acetate, and water is added for extraction. The residue is washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent is removed under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound No. 7.
[0050] (Synthesis of compound No. 8) Compound No. 7 is dissolved in methanol, and sodium methoxide / methanol solution is added under ice cooling, followed by stirring at room temperature. Hydrochloric acid is added under ice cooling to neutralize, and the solvent is distilled off under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound No. 8 (thymine derivative).
[0051] The compound represented by the above general formula (5) can be synthesized by first preparing a uracil derivative in which an azidomethyl group has been introduced at the 1-position of uracil as shown below, and then using this uracil derivative.
[0052] [ka]
[0053] (Synthesis of Compound No. 9) Uracil and cesium iodide are suspended in acetonitrile, N,O-bis(trimethylsilyl)acetamide is added, and the mixture is stirred at about 80°C. After cooling to room temperature, benzyloxymethyl chloride is added under ice cooling and the mixture is stirred at room temperature. Methanol is added under ice cooling, and the solvent is distilled off under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound number 9.
[0054] (Synthesis of compound No. 10) Compound No. 9 is suspended in chloroform and dissolved by heating to about 50°C. Iodotrimethylsilane is added, and the mixture is heated to reflux. After cooling to room temperature, the precipitated solid is collected by suction filtration to obtain a mixture containing compound No. 10.
[0055] (Synthesis of compound No. 11) A mixture containing compound number 10 is suspended in acetone. Sodium azide is added under ice cooling, and the mixture is stirred at room temperature. Insoluble matter is removed by suction filtration, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound number 11 (uracil derivative).
[0056] The compound represented by the above general formula (6) can be synthesized using the compound of compound number 11 (uracil derivative) as shown below.
[0057] [ka]
[0058] (Synthesis of compound No. 12) Compound No. 11 (uracil derivative) is suspended in acetonitrile, 2,4,6-triisopropylbenzenesulfonyl chloride, 4-dimethylaminopyridine and triethylamine are added, and the mixture is stirred at room temperature. Ammonia water is added under ice cooling, and the mixture is stirred at room temperature. Compound No. 12 (cytosine derivative) can be obtained by filtering the precipitated solid with suction. Compound No. 12 (cytosine derivative) can also be obtained by concentrating the filtrate under reduced pressure, and purifying the residue by silica gel column chromatography.
[0059] In the above general formula (1), a compound having a structure in which X is guanine and a 1,2,3-triazole ring is bonded to the carbon at position 7 of guanine via a methyl group can be synthesized by first preparing guanine derivative 1 in which an azidomethyl group is introduced at position 7 of guanine as shown below, and then using this guanine derivative 1.
[0060] [ka]
[0061] (Synthesis of compound No. 13) 2-Amino-6-chloropurine is suspended in acetonitrile, N,O-bis(trimethylsilyl)acetamide is added, and the mixture is heated to reflux. After cooling to room temperature, pivaloyloxymethyl azide and trimethylsilyl trifluoromethanesulfonate are added under ice cooling, and the mixture is stirred at about 70°C. Trimethylamine is added under ice cooling, and the solvent is distilled off under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound number 13.
[0062] (Synthesis of compound No. 14) Compound No. 13 is suspended in 1M hydrochloric acid and stirred at about 80° C. Methanol is added, and the solvent is removed under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound No. 14 (guanine derivative 1).
[0063] The compound represented by the above general formula (3) can be synthesized by first preparing guanine derivative 2 in which an azidomethyl group is introduced at the 9-position of guanine as shown below, and then using this guanine derivative 2.
[0064] [ka]
[0065] (Synthesis of compound No. 15) N 2 ,9-Diacetylguanine and diphenylcarbamyl chloride are suspended in pyridine, N,N-diisopropylethylamine is added dropwise under ice cooling, and the mixture is stirred at room temperature. Water is added under ice cooling, and the solvent is removed under reduced pressure. Ethanol and water (1:1) are added to the residue, and the mixture is stirred at about 95°C. After cooling to room temperature, the precipitated solid is collected by suction filtration to obtain compound number 15.
[0066] (Synthesis of compound No. 16) Compound No. 15 is suspended in 1,2-dichloroethane, N,O-bis(trimethylsilyl)acetamide is added, and the mixture is stirred at about 80°C. After cooling to room temperature, pivaloyloxymethyl azide and trimethylsilyl trifluoromethanesulfonate are added under ice cooling, and the mixture is stirred at about 80°C. Trimethylamine is added under ice cooling, and the solvent is distilled off under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound No. 16.
[0067] (Synthesis of compound No. 17) Compound No. 16 is suspended in methanol, and aqueous ammonia is added, followed by stirring at room temperature. Insoluble matter is removed by suction filtration, and the solvent is distilled off under reduced pressure. The residue is purified by silica gel column chromatography to obtain compound No. 17 (guanine derivative 2).
[0068] (Synthesis of 1,2,3-triazole compounds) The 1,2,3-triazole compound represented by the above general formula (2) can be synthesized by, for example, Method 1 or Method 2 shown below, using Compound No. 3 (adenine derivative) as a starting material.
[0069] (Method 1) Compound No. 3 (nucleobase derivative) is dissolved in N,N-dimethylformamide, and a terminal alkyne is added. Then, an aqueous solution of copper sulfate pentahydrate and an aqueous solution of sodium ascorbate are added, and the mixture is stirred at room temperature. After the solvent is distilled off under reduced pressure, the residue is purified by silica gel column chromatography to obtain the 1,2,3-triazole compound represented by the above general formula (2).
[0070] (Method 2) A mixture of compound No. 3 (nucleobase derivative), terminal alkyne, Cu / HP20, and Et3N is suspended in toluene and stirred at room temperature. After adding methanol, insoluble matter is removed by suction filtration, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography to obtain the 1,2,3-triazole compound represented by the above general formula (2).
[0071] The 1,2,3-triazole compound represented by the above general formula (4) can be synthesized by using the compound of compound number 8 (thymine derivative) as a starting material, for example, in the above-mentioned method 2, by using the compound of compound number 8 instead of the compound of compound number 3.
[0072] The 1,2,3-triazole compound represented by the above general formula (5) can be synthesized by using the compound of compound number 11 (uracil derivative) as a starting material, for example, in the above-mentioned method 2, by using the compound of compound number 11 instead of the compound of compound number 3.
[0073] The 1,2,3-triazole compound represented by the above general formula (6) can be synthesized by using the compound of compound number 12 (cytosine derivative) as a starting material, for example, in the above-mentioned method 2, by using the compound of compound number 12 instead of the compound of compound number 3.
[0074] The compound obtained in each of the above steps may be used in the next reaction as the reaction solution, or may be used in the next reaction after being recovered as a crude product. In each of the above steps, the compound may be isolated and purified from the reaction mixture by a conventional method such as concentration, recrystallization, distillation, solvent extraction, fractional distillation, chromatography, etc.
[0075] According to another aspect of the present disclosure, an antiviral agent containing a 1,2,3-triazole compound or a salt thereof is provided. As shown in the examples below, the 1,2,3-triazole compound of the present disclosure exhibits antiviral activity against viruses. Therefore, the 1,2,3-triazole compound of the present disclosure can be used as an antiviral agent. In addition, as shown in the examples below, the 1,2,3-triazole compound of the present disclosure has low toxicity to host cells. The 1,2,3-triazole compound of the present disclosure can be used as a pharmaceutical composition as it is or mixed with a pharmacologically acceptable carrier or the like. This pharmaceutical composition is useful as a preventive agent for viral infections and a therapeutic agent for viral infections.
[0076] The types of viruses to be used are not particularly limited, but include, for example, DNA viruses and RNA viruses.
[0077] In the present disclosure, DNA viruses include double-stranded DNA viruses and single-stranded DNA viruses. Examples of double-stranded DNA viruses include, but are not limited to, herpes viruses, pox viruses, adenoviruses, papilloma viruses, polyoma viruses, and hepatitis B viruses. Examples of herpes viruses include, but are not limited to, viruses belonging to the alpha herpesvirinae, beta herpesvirinae, and gamma herpesvirinae. Examples of viruses belonging to the alpha herpesvirinae include, but are not limited to, herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. Examples of viruses belonging to the beta herpesvirinae include, but are not limited to, cytomegalovirus, human herpesvirus 6, and human herpesvirus 7. Examples of viruses belonging to the gamma herpesvirinae include, but are not limited to, EB virus, human herpesvirus 8, and the like. Examples of poxviruses include, but are not limited to, vaccinia virus, molluscum contagiosum virus, etc. Examples of single-stranded DNA viruses include, but are not limited to, parvovirus.
[0078] In the present disclosure, the RNA virus includes single-stranded RNA virus, double-stranded RNA virus, and RNA-DNA virus. The single-stranded RNA virus includes, but is not limited to, positive-stranded RNA virus, negative-stranded RNA virus, etc. The positive-stranded RNA virus includes, but is not limited to, togavirus, flavivirus, coronavirus, etc. The togavirus includes, but is not limited to, Sindbis virus, rubella virus, etc. The flavivirus includes, but is not limited to, Japanese encephalitis virus, yellow fever virus, hepatitis C virus, etc. The negative-stranded RNA virus includes, but is not limited to, rhabdovirus, filovirus, paramyxovirus, orthomyxovirus, bunyavirus, arenavirus, etc. The rhabdovirus includes, but is not limited to, rabies virus, vesicular stomatitis virus, etc. The filovirus includes, but is not limited to, Ebola virus, Marburg virus, etc. Examples of paramyxoviruses include, but are not limited to, Sendai virus, measles virus, RS virus, mumps virus, etc. Examples of orthomyxoviruses include, but are not limited to, influenza virus. Examples of bunyaviruses include, but are not limited to, hemorrhagic fever with renal syndrome virus. Examples of arenaviruses include, but are not limited to, lymphocytic choriomeningitis virus. Examples of double-stranded RNA viruses include, but are not limited to, reovirus. Examples of RNA-DNA viruses include, but are not limited to, retrovirus.
[0079] The virus species to be applied is preferably a DNA virus, more preferably a double-stranded DNA virus, even more preferably a herpes virus, and particularly preferably a virus belonging to the α-herpesvirinae or β-herpesvirinae subfamily. The 1,2,3-triazole compound containing adenine can be particularly preferably used for viruses belonging to the α-herpesvirinae subfamily. The 1,2,3-triazole compound containing thymine, uracil or cytosine can be particularly preferably used for viruses belonging to the β-herpesvirinae subfamily.
[0080] In the present disclosure, "antiviral activity" means an activity to eliminate a virus or suppress its proliferation in a cell (host cell) infected with the virus, and for example, an activity to suppress viral replication in a host cell. The mechanism by which the 1,2,3-triazole compound of the present disclosure has antiviral activity is unclear. However, one of the presumed mechanisms is that the compound exerts an inhibitory effect in the form of a triphosphate. More specifically, it is presumed that the compound exerts antiviral activity by being triphosphorylated by thymidine kinase or a cell-derived phosphorylating enzyme expressed during the proliferation of the virus, and that the triphosphate exerts antiviral activity by inhibiting viral gene synthesis. That is, since the structure triphosphorylated by thymidine kinase or the like resembles the structure of nucleoside triphosphate (dNTP), which is a substrate for enzymes such as viral DNA polymerase and RNA polymerase, it is presumed that the compound is incorporated into DNA polymerase or RNA polymerase instead of dNTP, thereby inhibiting the activity of these enzymes. When the above triphosphate binds to the viral DNA strand or RNA strand, the elongation of the viral DNA strand or RNA strand stops. In order for DNA polymerase inhibitors and RNA polymerase inhibitors to be effective, they need to be phosphorylated by virus-derived thymidine kinase in virus-infected cells, and therefore, it is believed that the antiviral agent containing the 1,2,3-triazole compound of the present disclosure has little effect on non-virus-infected cells.
[0081] The antiviral agent containing the 1,2,3-triazole compound of the present disclosure may be formulated by known pharmaceutical methods.The antiviral agent containing the 1,2,3-triazole compound of the present disclosure may be used orally or parenterally, for example, as capsules, tablets, pills, liquids, powders, granules, fine granules, film coating agents, pellets, lozenges, sublingual agents, chewable agents, buccal agents, pastes, syrups, suspensions, elixirs, emulsions, liniments, ointments, plasters, poultices, transdermal preparations, lotions, inhalants, aerosols, injections, suppositories, etc.
[0082] In the formulation of an antiviral agent containing the 1,2,3-triazole compound of the present disclosure, the compound may be appropriately combined with a pharmacologically acceptable carrier, medium, additive, etc. Examples of carriers include, but are not limited to, solid carriers such as lactose, kaolin, sucrose, crystalline cellulose, corn starch, talc, agar, pectin, stearic acid, magnesium stearate, lecithin, sodium chloride, etc., and liquid carriers such as glycerin, peanut oil, polyvinylpyrrolidone, olive oil, ethanol, benzyl alcohol, propylene glycol, water, etc. Examples of media include, but are not limited to, sterilized water, physiological saline, vegetable oil, solvents, etc. The additives are not particularly limited, but examples thereof include emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, fragrances, excipients, vehicles, preservatives, binders, diluents, isotonicity agents, soothing agents, bulking agents, disintegrants, buffers, coating agents, lubricants, colorants, sweeteners, thickeners, flavoring agents, dissolution aids, etc. The content of the 1,2,3-triazole compound in the pharmaceutical preparation is not particularly limited, but may be, for example, about 0.01% by mass to about 100% by mass of the entire preparation.
[0083] The antiviral agent containing the 1,2,3-triazole compound of the present disclosure may be in the form of a kit in combination with other antiviral agents or pharmaceutical compositions. The antiviral agent containing the 1,2,3-triazole compound of the present disclosure may be used in combination with other antiviral agents or pharmaceutical compositions. The antiviral therapy using the antiviral agent or pharmaceutical composition containing the 1,2,3-triazole compound of the present disclosure may be used in combination with other therapies such as immunotherapy.
[0084] Preferred administration forms of the antiviral agent or pharmaceutical composition containing the 1,2,3-triazole compound of the present disclosure include, but are not limited to, oral or parenteral administration, more specifically, intravenous administration, intraarterial administration, intraperitoneal administration, subcutaneous administration, intradermal administration, intratracheal administration, rectal administration, intramuscular administration, administration by infusion, and the like.
[0085] When administering an antiviral agent containing a 1,2,3-triazole compound of the present disclosure, the dosage may be appropriately selected depending on the age, body weight, symptoms, health condition, severe condition, drug tolerance, administration form, etc. of the subject. The daily dosage of the antiviral agent containing a 1,2,3-triazole compound of the present disclosure is, for example, 0.001 to 2000 mg / kg body weight, preferably 0.01 to 1000 mg / kg body weight, more preferably 0.1 to 500 mg / kg body weight as the amount of the 1,2,3-triazole compound as an active ingredient, and may be administered to the subject once or in multiple doses. For example, when the subject is an adult, 10 mg to 2000 mg per dose may be orally administered 1 to 7 times a day, preferably 100 mg to 1000 mg per dose 3 to 5 times a day. Based on the above dosage and administration form, a method for preventing a viral infection and a method for treating a viral infection are provided.
[0086] The antiviral agent containing the 1,2,3-triazole compound of the present disclosure can be used for humans, but can also be used for animals other than humans, such as monkeys, mice, rats, rabbits, dogs, cats, sheep, goats, horses, cows, pigs, etc. EXAMPLES
[0087] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples.
[0088] 1. Synthesis of adenine derivatives The adenine derivatives were synthesized by the following method.
[0089] [ka]
[0090] Adenine (4.06 g, 32.2 mmol) was suspended in distilled water (132 mL), sodium hydroxide (258 mg, 6.44 mmol) was added, and then 37% formaldehyde aqueous solution (2.60 mL, 51.5 mmol) was added and stirred at room temperature for 2.5 hours. The precipitated solid was washed with water and collected by suction filtration to obtain Compound No. 1 (3.48 g, 65%) as a colorless solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.15 (s, 1H, H-8), 8.15 (s, 1H, H-2), 7.19 (s, 2H, NH2), 6.73 (t, J = 6.7 Hz, 1H, OH), 5.48 (d, J = 6.7 Hz, 2H, CH2); 13 C NMR (100 MHz, DMSO-d6) δ 156.0, 152.6, 149.1, 140.7, 118.6, 65.6; HRMS (ESI) Calcd for C6H8N5O [M+H] + : 166.0729. Found: 166.0731.
[0091] Compound No. 1 (832 mg, 5.03 mmol) was suspended in N,N-dimethylformamide (40 mL), and thionyl chloride (980 μL, 15.0 mmol) was added dropwise under ice cooling, followed by stirring at room temperature for 24 hours. Water was added under ice cooling to decompose the excess thionyl chloride, and the solvent was distilled off under reduced pressure. The precipitated solid was collected by suction filtration to obtain compound No. 2 (894 mg, 97%) as a colorless solid. 1 H NMR (400 MHz, DMSO-d6) δ 11.4 (d, J = 1.2 Hz, 1H, NH), 9.92 (d, J = 1.2 Hz, 1H, NH), 8.73 (s, 1H, H-8), 8.68 (s, 1H, H-2), 6.29 (s, 2H, CH2); 13 C NMR (100 MHz, DMSO-d6) δ 151.3, 148.2, 147.0, 143.2, 118.6, 50.2; HRMS (ESI) Calcd for C6H7ClN5[M+H] + : 184.0390. Found: 184.0383.
[0092] Compound No. 2 (918 mg, 5.0 mmol) was suspended in DMSO (15 mL), sodium azide (982 mg, 15.0 mmol) was added, and the mixture was stirred at 80° C. for 24 hours. The mixture was diluted with ethyl acetate and extracted with saturated saline. The mixture was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The precipitated solid was collected by suction filtration to obtain Compound No. 3 (adenine derivative) (314 mg, 33%) as a colorless solid. 1H NMR (400 MHz, DMSO-d6) δ 8.27 (s, 1H, H-8), 8.18 (s, 1H, H-2), 7.34 (s, 2H, NH2), 5.66 (s, 2H, CH2); 13 C NMR (100 MHz, DMSO-d6) δ 156.1, 153.1, 149.5, 140.5, 118.6, 57.0; HRMS (ESI) Calcd for C6H7N8[M+H] +: 191.0794. Found: 191.0784.
[0093] 2. Synthesis of thymine derivatives The thymine derivatives were synthesized by the following method.
[0094] [ka]
[0095] Thymine (3.79 g, 30.1 mmol) was suspended in pyridine (10.8 mL) and acetonitrile (32.4 mL), and benzoyl chloride (7.3 mL, 62.8 mmol) was added dropwise under ice cooling, followed by stirring at room temperature for 48 hours. Methanol (10 mL) was added and the mixture was stirred for 2 hours, after which the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1 to 0:1) to obtain compound number 4 (6.46 g, 93%) as a colorless solid. 1 H NMR (400 MHz, DMSO-d6) δ = 11.36 (s, 1H, NH), 7.93 (d, J = 8.0 Hz, 2H. H-Ph), 7.77 (t, J = 8.0 Hz, 1H, H-Ph), 7.59 (t, J = 8.0 Hz, 2H, H-Ph), 7.53 (d, J = 1.0 Hz, 1H, H-6), 1.81 (d, J = 1.0 Hz, 3H, CH3).
[0096] Compound No. 4 (2.30 g, 10.0 mmol) was suspended in 37% aqueous formaldehyde solution (20 mL) and heated under reflux for 3 hours. After cooling to room temperature, the mixture was left in a refrigerator for 24 hours. The precipitated solid was washed with 3% aqueous formaldehyde solution and collected by suction filtration to obtain Compound No. 5 (1.86 g, 71%) as a colorless solid. 1H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J = 8.0 Hz, 2H, H-Ph), 7.80-7.75 (m, 2H, H-6, H-Ph), 7.60 (t, J = 8.0 Hz, 2H, H-Ph), 6.76 (t, J = 8.0 Hz, 1H, OH), 5.07 (d, J = 8.0 Hz, 2H, CH2), 1.85 (d, J = 1.2 Hz, 3H, CH3); 13 HRMS (ESI) Calcd for C 13 H 12 N2NaO4[M+Na] + : 283.0695. Found: 283.0693.
[0097] Compound No. 5 (267 mg, 1.02 mmol) was dissolved in N,N-dimethylformamide (10 mL), and thionyl chloride (210 μL, 2.89 mmol) was added dropwise under ice cooling, followed by stirring at room temperature for 3 hours. Water was added under ice cooling, and the mixture was neutralized with a saturated aqueous solution of sodium bicarbonate. After dilution with chloroform, a saturated aqueous solution of sodium bicarbonate was added and extracted. The mixture was washed with saturated saline, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1) to obtain compound No. 6 (253 mg, 89%) as a colorless solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.97-7.95 (m, 3H, H-6, H-Ph), 7.80 (t, J = 7.8 Hz, 1H, H-Ph), 7.62 (t, J = 7.8 Hz, 2H, H-Ph), 5.72 (s, 2H, CH2), 1.86 (d, J = 1.2 Hz, 3H, CH3); 13HRMS (ESI) Calcd for C 13 H 11 ClN2NaO3[M+Na] + : 301.0356. Found: 301.0354.
[0098] Compound No. 6 (164 mg, 0.59 mmol) was dissolved in acetone (6 mL), sodium azide (77.1 mg, 1.18 mmol) was added, and the mixture was stirred at room temperature for 24 hours. Insoluble matter was removed by suction filtration, and the filtrate was concentrated under reduced pressure. The residue was diluted with ethyl acetate, and water was added for extraction. The mixture was washed with saturated saline and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1) to obtain compound No. 7 (166 mg, 99%) as a colorless solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.98 (d, J = 7.7 Hz, 2H, H-Ph), 7.88 (d, J = 1.2 Hz, 1H, H-6), 7.79 (t, J = 7.7 Hz, 1H, H-Ph), 7.60 (t, J = 7.7 Hz, 2H, H-Ph), 5.21 (s, 2H, CH2), 1.84 (d, J = 1.2 Hz, 3H, CH3); 13 HRMS (ESI) Calcd for C 13 H 11 N5NaO3[M+Na] + : 308.0760. Found: 308.0750.
[0099] Compound No. 7 (298 mg, 1.04 mmol) was dissolved in methanol (10.4 mL), and 28% sodium methoxide / methanol solution (38.6 μL, 20.8 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 18 hours. After neutralization with 1 M hydrochloric acid under ice cooling, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1) to obtain compound No. 8 (162 mg, 86%) as a colorless solid. 1 H NMR (400 MHz, DMSO-d6) δ 11.5 (s, 1H, NH), 7.61 (d, J = 1.2 Hz, 1H, H-6), 5.12 (s, 2H, CH2), 1.75 (d, J = 1.2 Hz, 3H, CH3); 13 C NMR (100 MHz, DMSO-d6) δ 164.2, 151.2, 140.2, 109.6, 62.1, 11.9; HRMS (ESI) Calcd for C6H6N5O2[MH] - : 180.0521. Found: 180.0520.
[0100] 3. Synthesis of uracil derivatives The uracil derivatives were synthesized by the following method.
[0101] [ka]
[0102] Uracil (560mg, 5.0mmol) and cesium iodide (1.30g, 5.0mmol) were suspended in acetonitrile (5.0mL), N,O-bis(trimethylsilyl)acetamide (2.5mL, 10.0mmol) was added, and the mixture was stirred at 80°C for 1 hour. After cooling to room temperature, benzyloxymethyl chloride (755μL, 5.5mmol) was added under ice cooling, and the mixture was stirred at room temperature for 14 hours. Methanol was added under ice cooling, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1 to 1:2) to obtain compound No. 9 (966mg, 83%) as a colorless solid. 1 H NMR (400 MHz, DMSO-d6) δ 11.32 (s, 1H, NH), 7.71 (d, J = 7.8 Hz, 1H, H-6), 7.33-7.29 (m, 5H, H-Ph), 5.59 (d, J = 7.8 Hz, 1H, H-5), 5.16 (s, 2H, OCH2N), 4.55 (s, 2H, OCH2Ph); 13 C NMR (100 MHz, DMSO-d6) δ 163.7, 151.1, 144.9, 137.5, 128.3, 127.7, 127.6, 101.7, 76.2, 70.3; 12 H 11 N2O3[MH] - : 231.0770. Found: 231.0752.
[0103] Compound No. 9 (929 mg, 4.0 mmol) was suspended in chloroform (10 mL) and dissolved by heating to 50° C. Iodotrimethylsilane (2.3 mL, 17.0 mmol) was added, and the mixture was heated under reflux for 20 hours. After cooling to room temperature, the precipitated solid was collected by suction filtration to obtain a mixture (955 mg) containing compound No. 10. This mixture was used in the next step as it was without purification.
[0104] A mixture (951 mg) containing compound No. 10 was suspended in acetone (18 mL). Sodium azide (735 mg, 11.0 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 6 hours. Insoluble matter was removed by suction filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1 to 1:2) to obtain compound No. 11 (575 mg, 86%, over 2 steps) as a colorless solid. 1 H NMR (400 MHz, DMSO-d6) δ 11.49 (s, NH), 7.72 (d, J = 8.2 Hz, 1H, H-6), 5.63 (d, J = 8.2 Hz, 1H, H-5), 5.15 (s, 2H, CH2); 13 C NMR (100 MHz, DMSO-d6) δ 163.6, 151.2, 144.7, 102.0, 62.3; HRMS (ESI) Calcd for C5H4N5O2[MH] - Found: 166.0365.
[0105] 4. Synthesis of cytosine derivatives The cytosine derivative was synthesized by the following method.
[0106] [ka]
[0107] Compound No. 11 (334 mg, 2.0 mmol) was suspended in acetonitrile (10 mL), and 2,4,6-triisopropylbenzenesulfonyl chloride (1.21 g, 4.0 mmol), 4-dimethylaminopyridine (536 mg, 4.0 mmol), and triethylamine (555 μL, 4.0 mmol) were added, followed by stirring at room temperature for 1 hour. Ammonia water (5.0 mL) was added under ice cooling, and the mixture was stirred at room temperature for 19 hours. The precipitated solid was collected by suction filtration to obtain compound No. 12 (67.9 mg, 20%) as a colorless solid. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate:methanol=8:1) to obtain compound No. 12 (209 mg, 63%). 1 H NMR (400 MHz, DMSO-d6) δ 7.62 (d, J = 7.4 Hz, 1H, H-6), 7.32 (s, 1H, NH), 7.27 (s, 1H, NH), 5.69 (d, J = 7.4 Hz, 1H, H-5), 5.07 (s, 2H, CH2).
[0108] 5. Synthesis of 1,2,3-triazole compounds Using the obtained adenine derivatives, thymine derivatives, uracil derivatives, and cytosine derivatives, 1,2,3-triazole compounds were synthesized by the following method.
[0109] Example 1 A mixture of adenine derivative (47.6 mg, 250 μmol), propargyl alcohol (275 μmol) as a terminal alkyne, 1% Cu / HP20 (16.0 mg, 2.5 μmol), and triethylamine (38 μL, 275 μmol) was suspended in toluene (250 μL) and stirred at room temperature. After adding methanol, insoluble matter was removed by suction filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain the 1,2,3-triazole compound of Example 1 represented by the following formula (7) (hereinafter also referred to as "9mA"). 1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.20 (s, 1H), 8.18 (s, 1H), 7.36 (s, 2H), 6.75 (s, 2H), 5.19-5.17 (m, 1H), 4.47 (d, J = 5.5 Hz, 2H).
[0110] [ka]
[0111] Example 2 The adenine derivative (951 mg, 5.0 mmol) was dissolved in N,N-dimethylformamide (3.4 mL), and (S)-1-(4-ethynylphenyl)ethane-1,2-diol (892 mg, 5.5 mmol) was added as a terminal alkyne. 40 mM copper sulfate pentahydrate aqueous solution (10 mL) and 100 mM sodium ascorbate aqueous solution (4 mL) were added, and the mixture was stirred at room temperature. After the solvent was distilled off under reduced pressure, the residue was purified by silica gel column chromatography (chloroform:methanol) to obtain the 1,2,3-triazole compound of Example 2 represented by the following formula (8) (hereinafter also referred to as "9SMA"). 1 H NMR (400 MHz, DMSO-d6) δ 8.75 (s, 1H), 8.46 (s, 1H), 8.20 (s, 1H), 7.76 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 7.37 (s, 1H), 6.82 (s, 2H), 5.28 (d, J = 4.0 Hz, 1H), 4.74 (t, J = 5.6 Hz, 1H), 4.56-4.52 (m, 1H), 3.42 (t, J = 5.6 Hz, 1H).
[0112] [ka]
[0113] Example 3 The adenine derivative (951 mg, 5.0 mmol) was dissolved in N,N-dimethylformamide (3.4 mL), and (R)-1-(4-ethynylphenyl)ethane-1,2-diol (892 mg, 5.5 mmol) was added as a terminal alkyne. 40 mM copper sulfate pentahydrate aqueous solution (10 mL) and 100 mM sodium ascorbate aqueous solution (4 mL) were added, and the mixture was stirred at room temperature. After the solvent was distilled off under reduced pressure, the residue was purified by silica gel column chromatography (chloroform:methanol) to obtain the 1,2,3-triazole compound of Example 3 represented by the following formula (9) (hereinafter also referred to as "9RMA"). 1 H NMR (400 MHz, DMSO-d6) δ 8.75 (s, 1H), 8.46 (s, 1H), 8.20 (s, 1H), 7.76 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 7.37 (s, 1H), 6.82 (s, 2H), 5.28 (d, J = 4.0 Hz, 1H), 4.74 (t, J = 5.6 Hz, 1H), 4.56-4.52 (m, 1H), 3.42 (t, J = 5.6 Hz, 1H).
[0114] [ka]
[0115] Example 4 A 1,2,3-triazole compound of Example 4 represented by the following formula (10) (hereinafter also referred to as "1mT") was obtained in the same manner as in Example 1, except that a thymine derivative was used instead of an adenine derivative. 1 H NMR (400 MHz, DMSO-d6) δ 11.51 (s, 1H), 8.02 (s, 1H), 7.78 (d, J = 0.6 Hz, 1H), 6.18 (s, 2H), 5.21 (t, J = 5.7 Hz, 1H), 4.50 (d, J = 5.7 Hz, 2H), 1.76 (d, J = 0.6 Hz, 3H).
[0116] [ka]
[0117] Example 5 A 1,2,3-triazole compound of Example 5 represented by the following formula (11) (hereinafter also referred to as "1mU") was obtained in the same manner as in Example 1, except that a uracil derivative was used instead of an adenine derivative. 1 H NMR (400 MHz, DMSO-d6) δ 11.50 (s, 1H), 8.03 (s, 1H), 7.90 (d, J = 7.8 Hz, 1H), 6.22 (s, 2H), 5.67 (d, J = 7.8 Hz, 1H), 5.21 (t, J = 5.7 Hz, 1H), 4.50 (d, J = 5.7 Hz, 2H).
[0118] [ka]
[0119] Example 6 A 1,2,3-triazole compound of Example 6 represented by the following formula (12) (hereinafter also referred to as "1mC") was obtained in the same manner as in Example 1, except that a cytosine derivative was used instead of an adenine derivative. 1 H NMR (400 MHz, DMSO-d6) δ 7.99 (s, 1H), 7.82 (d, J = 7.2 Hz, 1H), 7.35 (s, 1H), 7.30 (s, 1H), 6.16 (s, 2H), 5.72 (d, J = 7.2 Hz, 1H), 5.18 (t, J = 5.9 Hz, 1H), 4.49 (d, J = 5.9 Hz, 2H).
[0120] [ka]
[0121] 6. Experiment The antiviral activity against herpes simplex virus was evaluated using 1mU, 9mA, 9SMA, and 9RMA. Cytotoxicity was also evaluated.
[0122] (1) Method for evaluating antiviral activity Vero cells derived from African green monkey kidneys were seeded semi-confluently on 6-well plates the day before infection. The cells were cultured in DMEM medium containing 5% calf serum at 37°C in the presence of 5% CO2. 30 minutes before infection, DMSO solutions of 1,2,3-triazole compounds were added to the wells. The concentrations were 100 μM, 10 μM, and 1 μM. As a control, DMSO solutions were added in place of the 1,2,3-triazole compounds. Then, the Vero cells were infected with herpes simplex virus type 1 HSV-1 (F strain) and cultured at 37°C for 72 hours. 72 hours after infection, the cells were fixed with formalin and stained with crystal violet. The plaques in each well were observed and counted. The antiviral activity was evaluated based on the degree of reduction in plaques compared to the control.
[0123] (2) Antiviral activity evaluation results FIG. 1 is an explanatory diagram showing the results of the antiviral activity evaluation. In FIG. 1, the vertical axis indicates the number of counted plaques. It was found that all of the 1,2,3-triazole compounds used in the experiment had a smaller number of plaques than DMSO as a control, and thus inhibited viral proliferation. This demonstrated that the 1,2,3-triazole compounds have antiviral activity.
[0124] (3) Method of cytotoxicity evaluation African green monkey kidney-derived Vero cells were diluted to 1 × 10 4Cells / well were seeded on a 96-well plate. The cells were cultured at 37°C in the presence of 5% CO2 using DMEM medium containing 5% calf serum. On the day of the culture, DMSO solutions of 1,2,3-triazole compounds were added to the wells. The concentrations were 100 μM and 10 μM. As a control, DMSO solutions were added in place of the 1,2,3-triazole compounds. Culture was carried out at 37°C for 24 hours. The number of cells was 5. After 24 hours of culture, the number of live cells was compared using the CellTiter 96 AQueous One Solution Reagent kit (MTS assay: colorimetric quantitative analysis of live cells) manufactured by Promega. The relative value of the number of live cells was calculated when the number of live cells in the control was set to 1.
[0125] (4) Cytotoxicity evaluation results FIG. 2 is an explanatory diagram showing the results of the cytotoxicity evaluation. In FIG. 2, the vertical axis indicates the relative value of the number of viable cells. None of the 1,2,3-triazole compounds used in the experiment clearly inhibited cell proliferation. From the results of the antiviral activity evaluation and the cytotoxicity evaluation, it was found that the 1,2,3-triazole compounds have antiviral activity and low cytotoxicity.
[0126] The present disclosure is not limited to the above-mentioned embodiment, and can be realized in various configurations without departing from the spirit of the present disclosure. For example, the technical features in each embodiment corresponding to the technical features in each form described in the Summary of the Invention column can be appropriately replaced or combined in order to solve some or all of the above-mentioned problems or to achieve some or all of the above-mentioned effects. Furthermore, if the technical feature is not described as essential in this specification, it can be appropriately deleted.
Claims
1. General formula (1): 【Chemistry 1】 (In the formula, X represents one member selected from the group consisting of adenine, thymine, uracil, cytosine, and guanine; R represents an alkyl group having 1 to 4 carbon atoms and substituted with a substituent, or an aryl group substituted with the aforementioned substituent, and the aforementioned substituent is a hydroxyl group, or an alkyl group having 1 to 4 carbon atoms and substituted with a hydroxyl group.) or a salt thereof.
2. X is adenine; The 1,2,3-triazole compound or a salt thereof according to claim 1.
3. X is a member selected from the group consisting of thymine, uracil, and cytosine; The 1,2,3-triazole compound or a salt thereof according to claim 1.
4. R is an aryl group substituted with the above-mentioned substituents; The 1,2,3-triazole compound or a salt thereof according to claim 2.
5. R is a phenyl group substituted with the above-mentioned substituents; The 1,2,3-triazole compound or a salt thereof according to claim 4.
6. the substituent is an alkyl group having 2 to 3 carbon atoms and substituted with two or more hydroxyl groups; The 1,2,3-triazole compound or a salt thereof according to claim 4 or 5.
7. R is an alkyl group having 1 to 2 carbon atoms substituted with the substituent. The 1,2,3-triazole compound or a salt thereof according to claim 2.
8. the substituent is a hydroxyl group; The 1,2,3-triazole compound or a salt thereof according to claim 7.
9. An antiviral agent comprising the 1,2,3-triazole compound or a salt thereof according to any one of claims 1 to 3.
Citation Information
Patent Citations
Method for preparing sterile ointment containing acyclovir
JP2004503485A
